Overcoming multiple drug resistance mechanisms in medulloblastoma

Othman, Ramadhan; Coyle, Beth; Kimishi, Ioanna; Bradshaw, Tracey D.; Storer, Lisa; Korshunov, Andrey; Pfister, Stefan; Grundy, Richard; Kerr, Ian D.

Abstract

© 2014 Othman et al.; licensee BioMed Central Ltd. Introduction: Medulloblastoma (MB) is the most common malignant paediatric brain tumour. Recurrence and progression of disease occurs in 15-20% of standard risk and 30-40% of high risk patients. We analysed whether circumvention of chemoresistance pathways (drug export, DNA repair and apoptotic inhibition) can restore chemotherapeutic efficacy in a panel of MB cell lines. Results: We demonstrate, by immunohistochemistry in patient tissue microarrays, that ABCB1 is expressed in 43% of tumours and is significantly associated with high-risk. We show that ABCB1, O6-methylguanine-DNA-methyltransferase (MGMT) and BCL2 family members are differentially expressed (by quantitative reverse transcription polymerase chain reaction, Western blotting and flow cytometry) in MB cell lines. Based on these findings, each pathway was then inhibited or circumvented and cell survival assessed using clonogenic assays. Inhibition of ABCB1 using vardenafil or verapamil resulted in a significant increase in sensitivity to etoposide in ABCB1-expressing MB cell lines. Sensitivity to temozolomide (TMZ) was MGMT-dependent, but two novel imidazotetrazine derivatives (N-3 sulfoxide and N-3 propargyl TMZ analogues) demonstrated ≥7 fold and ≥3 fold more potent cytotoxicity respectively compared to TMZ in MGMT-expressing MB cell lines. Activity of the BAD mimetic ABT-737 was BCL2A1 and ABCB1 dependent, whereas the pan-BCL2 inhibitor obatoclax was effective as a single cytotoxic agent irrespective of MCL1, BCL2, BCL2A1, or ABCB1 expression. Conclusions: ABCB1 is associated with high-risk MB; hence, inhibition of ABCB1 by vardenafil may represent a valid approach in these patients. Imidazotetrazine analogues of TMZ and the BH3 mimetic obatoclax are promising clinical candidates in drug resistant MB tumours expressing MGMT and BCL2 anti-apoptotic members respectively.

Citation

Othman, R., Coyle, B., Kimishi, I., Bradshaw, T. D., Storer, L., Korshunov, A., Pfister, S., Grundy, R., & Kerr, I. D. (2014). Overcoming multiple drug resistance mechanisms in medulloblastoma. Acta Neuropathologica Communications, 2(1), Article 57. https://doi.org/10.1186/2051-5960-2-57

• Journal Article Type: Article
• Acceptance Date: May 17, 2014
• Online Publication Date: May 30, 2014
• Publication Date: Jan 27, 2014
• Deposit Date: Jul 18, 2018
• Journal: Acta Neuropathologica Communications
• Electronic ISSN: 2051-5960
• Publisher: Springer Verlag
• Peer Reviewed: Peer Reviewed
• Volume: 2
• Issue: 1
• Article Number: 57
• DOI: https://doi.org/10.1186/2051-5960-2-57
• Public URL: https://nottingham-repository.worktribe.com/output/1104494
• Publisher URL: https://actaneurocomms.biomedcentral.com/articles/10.1186/2051-5960-2-57
• PMID: 24887326